Nexalis Screens First Patient in Phase 2 Trial for Breakthrough Cancer Pain

Phase 2 Trial Launch Marks Key Clinical Milestone

Nexalis Therapeutics (ASX:NX1) has taken a significant step forward in developing IRX-211, its inhaled therapy for Breakthrough Cancer Pain (BTcP), by screening the first patient in its Phase 2 clinical trial. This milestone signals the transition of IRX-211 into a controlled clinical evaluation within its target population: opioid-tolerant cancer patients experiencing rapid onset breakthrough pain despite stable background opioid therapy.

The trial design is robust; a multicentre, randomised, double-blind, placebo-controlled cross-over study with an initial open-label titration phase. It aims to enrol approximately 156 patients, with at least half expected to achieve an effective personalised dose before entering the blinded cross-over phase. This approach allows within-patient comparisons of IRX-211’s efficacy and safety, a critical factor given the subjective and rapid nature of BTcP episodes.

Addressing a Large and Growing Market Opportunity

Breakthrough Cancer Pain remains a challenging clinical problem with few effective rapid-onset treatment options. Current opioid therapies often lag behind the swift escalation of pain episodes, leaving patients inadequately managed. IRX-211’s proprietary inhaled delivery aims to close this gap by providing fast, predictable, and patient-controlled relief.

The global cancer pain market is substantial and expanding, with forecasts estimating growth from US$8.87 billion in 2026 to nearly US$13 billion by 2032. This growing demand underscores the commercial potential of a successful BTcP therapy. Nexalis’ CEO Darryl Davies highlighted the trial as laying a strong foundation for demonstrating clinical benefit and positioning the program for future partnering discussions.

Building on a Solid Safety Profile and Pipeline Momentum

The Phase 1 program in healthy volunteers established IRX-211’s excellent safety profile, rapid systemic exposure, and consistent pharmacokinetics, supporting its progression into patient studies. This development comes amid Nexalis’ broader pipeline activity, including the recent launch of the first human trial for IRX-616a targeting panic disorder, which is also advancing through early clinical stages.

While Nexalis posted a loss of $1.83 million in 2025 reflecting increased development investment, it has secured funding facilities to accelerate these programs. The company’s strategic focus on rapid-onset therapies for unmet needs in pain and mental health markets could unlock significant shareholder value if clinical outcomes prove positive.

Investors will be watching closely as the Phase 2 trial progresses, particularly for early signals of efficacy and safety in this difficult-to-treat population. The trial’s cross-over design and patient-reported outcomes may provide nuanced insights into IRX-211’s real-world impact on breakthrough pain episodes.